Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial

被引：51

作者：

Cheng, Y. ^{[1
]}

Wang, Q. ^{[2
]}

Li, K. ^{[3
]}

Shi, J. ^{[4
]}

Wu, L. ^{[5
]}

Han, B. ^{[6
]}

Chen, G. ^{[7
]}

He, J. ^{[8
]}

Wang, J. ^{[9
]}

Qin, H. ^{[10
]}

Li, X. ^{[11
]}

机构：

[1] Jilin Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China

[2] Zhengzhou Univ, Affiliated Canc Hosp, Dept Internal Med, Zhengzhou, Henan, Peoples R China

[3] Tianjin Med Univ, Canc Hosp, Tianjin, Peoples R China

[4] Linyi City Tumor Hosp, Linyi, Peoples R China

[5] Hunan Canc Hosp, Dept Thorac Med Oncol, Changsha, Hunan, Peoples R China

[6] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[7] Harbin Med Univ, Canc Hosp, Dept Resp Med, Harbin, Heilongjiang, Peoples R China

[8] Guangzhou Med Univ, Affiliated Hosp 1, Thorac Surg, Guangzhou, Guangdong, Peoples R China

[9] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[10] 307 Hosp Mil Chinese Peoples Liberat Army, Beijing, Peoples R China

[11] Liaoning Canc Hosp & Inst, Shenyang, Liaoning, Peoples R China

来源：

关键词：

Anlotinib; 3rd line; relapsed SCLC;

D O I：

10.1016/j.jtho.2018.08.308

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA13.03

引用

页码：S351 / S352

页数：2